Tennor Therap-b (6872.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | - | - | 0 | 0 | 0 | 0 | - |
| Operating profit | CNY m | -119 | -38 | ||||||
| Net profit | CNY m | - | - | - | -192 | -146 | -153 | -38 | - |
| EPS reported | CNY | -2.96 | 0.00 | ||||||
| Operating cashflow per share | CNY | -1.68 | -1.68 | ||||||
| Capex per share | CNY | 0.01 | 0.01 | ||||||
| FCF per share | CNY | -1.69 | -1.69 | ||||||
| Free cash flow | CNY m | -88 | -18 | ||||||
| Net debt | CNY m | -157 | -157 | ||||||
| Book value equity | CNY m | 154 | 154 | ||||||
| Book value per share | CNY | 2.97 | 2.97 | ||||||
| Number of shares | m | 51.75 | - | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 63.75 | 63.75 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -111.91 | -551.49 | ||||||
| EV/EBITDA LTM | x | -64.28 | -260.33 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -1.56% | -2.06% | ||||||
| FCF Yield | % | -0.89% | -0.18% | ||||||
| Quality | |||||||||
| ROE | % | -99.60% | +41.18% | ||||||
| ROIC | % | -57.19% | -57.19% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.06 | -0.62 | ||||||
| Net Debt/EBITDA | x | 1.03 | 1.03 | ||||||
| EBIT/Net interest | x | -80.07 | -80.07 | ||||||
| Net debt/market cap | % | +0.27% | +0.36% | ||||||
| Net debt/Equity | x | -1.02 | -1.02 | ||||||
| Gross debt/equity | x | 0.19 | 0.19 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free